Pharmaceuticals

Transcenta to Present Interim Safety and Efficacy Data of the TST001 and Chemotherapy Combination Expansion Cohort for Claudin18.2 Positive First Line Gastric Cancer at ESMO Congress 2022

SUZHOU, China, July 28, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that the interim safe...

2022-07-28 08:00 3393

Plant-Oil-Based Skincare Technology Business Available for License or Purchase

A NEW AND UNIQUE ANHYDROUS SKINCARE TECHNOLOGY OF PROVEN VERY HIGH EFFICACY  AUCKLAND, New Zealand, July 27, 2022 /PRNewswire/ -- Invented and developed by the CEO ofFutecNZ Limited in New Zealand, (trading under the ONE24 brand) trialled and tested by accredited scientific laboratories, a vast t...

2022-07-28 05:22 2295

BAMF Health and Telix complete first total-body PET scans with Illuccix for prostate cancer imaging

Telix and BAMF Health use Illuccix® (kit for the preparation of Gallium Ga 68 gozetotide injection) for the first time with uEXPLORER® total-body PET scanner for prostate cancer imaging GRAND RAPIDS, Mich. and INDIANAPOLIS, July 27, 2022 /PRNewswire/ -- The PSMA-PET[1] imaging agent Illuccix® fr...

2022-07-27 20:30 3153

Samsung Biologics Reports Second Quarter 2022 Financial Results

* Released consolidated financial position of the company based on its full acquisition of Samsung Bioepis completed onApril 20, 2022 * Achieved record-high semi-annual revenue exceeding KRW 1 trillion * Recorded Q2'22 revenue of KRW 503.7 billion for the company's CDMO business * Recorded ...

2022-07-27 14:43 2849

Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants

Independent lab results demonstrate that the combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously demonstrated with all variants of concern to date The amubarvimab/romlusevimab combination is commercially available in China and is under rev...

2022-07-27 07:00 4501

Sustainable Manufacturing Practices: The Key to Mitigating Antimicrobial Resistance

JAKARTA, Indonesia, July 26, 2022 /PRNewswire/ -- Centrient Pharmaceuticals, a global business-to-business leader in sustainable, enzymatic antibiotics manufacturing, in partnership with Menjangan Sakti, a trader of pharmaceutical raw materials inIndonesia, organized a workshop on 'Sustainability...

2022-07-26 21:45 2798

Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan

* Nuvaxovid™ is the first protein-based COVID-19 vaccine approved for use in adolescents inJapan GAITHERSBURG, Md., July 26, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious d...

2022-07-26 20:05 3343

Henlius HANQUYOU Received TGA Approval in Australia

SHANGHAI, July 26, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the company's business partner Cipla Limited ("Cipla") has received the relevant registration certificates from the Therapeutic Goods Administration ofAustralia ("TGA") for the approval of Henlius' sel...

2022-07-26 18:03 4882

Nuance Pharma announces the completion of dosing for all NTM-001 Phase 1 clinical study participants in HKU Clinical Trials Centre

* All 16 healthy normal volunteers (HNVs) were dosed and no serious adverse event was reported * The NTM-001 Phase I clinical study is expected to be completed by the end of 2022 SHANGHAI, July 26, 2022 /PRNewswire/ -- Nuance Pharma ("the Company") announces the completion of dosing for all H...

2022-07-26 17:04 3248

Sirnaomics Receives IND Clearance from the "Taiwan Ministry of Health and Welfare" for Phase I Clinical Study of RNAi Therapeutic STP705 for Liver Cancer Treatment

GAITHERSBURG, Md. and SUZHOU, China, July 26, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Company has received regulatory clearance from t...

2022-07-26 16:58 3712

Molecular Diagnostics Developer INEX Innovate Announces Funding for New Research with The Chinese University of Hong Kong

Singapore-based diagnostics developer INEX Innovate brings The Chinese University of Hong Kong together to further research work on LEXI®, INEX's fetal cell based non-invasive pre-natal diagnostics technology. SINGAPORE, July 26, 2022 /PRNewswire/ -- Singapore-based diagnostics developer and med...

2022-07-26 08:30 3851

CSafe Global Continues Investment in Cell and Gene Therapy Solutions with Addition of New Portfolio President

Amy DuRoss joins CSafe Global as President, Cell & Gene Therapy to drive innovation and solution development MONROE, Ohio, July 26, 2022 /PRNewswire/ -- CSafe Global, the innovation leader in temperature-controlled shipping solutions for the transport of life-enhancing pharmaceuticals, announced...

2022-07-26 03:35 4366

Ascentage Pharma and Tanner Pharma Group Initiate a Global Innovative Named Patient Program

SUZHOU, China and ROCKVILLE, Md. and CHARLOTTE, N.C., July 25, 2022 /PRNewswire/ --Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, andTanner Ph...

2022-07-25 21:59 3186

Anti-PD-1 monoclonal antibody Puyouheng™ (HX-008, Pucotenlimab injection) Co-developed by LEPU BIOPHARMA and HANX BIOPHARMACEUTICALS was approved for marketing in China by NMPA

HANGZHOU, China, July 25, 2022 /PRNewswire/ -- Anti-PD-1 monoclonal antibody – PuyouhengTM (HX-008, pucotenlimab injection), was conditionally approved by the National Medical Products Administration (NMPA) for marketing inChina to treat patients with unresectable or metastatic microsatellite ins...

2022-07-25 18:47 2848

Rona Therapeutics Announces Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform

* Rona to advance worldwide development of Sanofi siRNA portfolio targeting liver and other tissues * Rona licensed Sanofi's siRNA platform to enable discovery programs in expanded therapeutic areas including neuro and muscular diseases, for which Sanofi has an exclusive option to acquire neu...

2022-07-25 12:30 4456

US FDA APPROVES QBIOTICS INVESTIGATIONAL NEW DRUG APPLICATION TO INITIATE TIGILANOL TIGLATE SOFT TISSUE SARCOMA PHASE II TRIAL

* Investigational new drug (IND) approval received by QBiotics, to initiate a Phase II clinical trial investigating tigilanol tiglate in the treatment of patients with Soft Tissue Sarcoma (STS) * The open label trial will evaluate efficacy and dose ranging in patients with advanced or metasta...

2022-07-25 07:09 3616

Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada

SUZHOU, China and ROCKVILLE, MD, July 21, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Phase Ib study of Ascentage Pharma's novel...

2022-07-22 07:59 3127

Congratulations! Kexing Biopharm (688136.SH) was awarded by the" Annual Top 20 Chinese Biopharmaceutical Entreprises"

SHENZHEN, China, July 21, 2022 /PRNewswire/ -- On 12 July 2022, Menet held the award ceremony of the "Annual Top 100 China's Pharmaceutical Entreprises in 2021", in which 5 sub-lists of the pharmaceutical industries had been announced. This event showcased the professionalism and influence of the...

2022-07-21 22:32 4867

Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy

– Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication – – Approval Follows Positive Opinion by European Committee for Medicinal Products for Human Use (CHMP) inMay 2022 – NEWTON, Mass. and FLORENCE, Italy, July 21, 2022 /PRNewswire/ -- Karyopha...

2022-07-21 21:25 4579

Telix Reports Second Quarter 2022 Financial Results

MELBOURNE, Australia, July 21, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended30 June 2022. All figures are in AUD$ unless otherwise stated. All fi...

2022-07-21 08:34 3625
1 ... 292293294295296297298 ... 350